Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% ...

Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese ...